PatientsVille.com Logo

HYPOKALAEMIA and COZAAR

PatientsVille

HYPOKALAEMIA Symptoms and Causes

Potassium is a mineral that your body needs to work properly. It is a type of electrolyte. It helps your nerves to function and muscles to contract. It helps your heartbeat stay regular. It also helps move nutrients into cells and waste products out of cells. A diet rich in potassium helps to offset some of sodium's harmful effects on blood pressure.

Many people get all the potassium they need from what they eat and drink. Sources of potassium in the diet include

  • Leafy greens, such as spinach and collards
  • Fruit from vines, such as grapes and blackberries
  • Root vegetables, such as carrots and potatoes
  • Citrus fruits, such as oranges and grapefruit

Your kidneys help to keep the right amount of potassium in your body. If you have chronic kidney disease, your kidneys may not remove extra potassium from the blood. Some medicines also can raise your potassium level. You may need a special diet to lower the amount of potassium that you eat.

Check out the latest treatments for HYPOKALAEMIA

HYPOKALAEMIA treatment research studies

COZAAR clinical trials, surveys and public health registries


Find Drug Side Effect reports



COZAAR Side Effects

Renal Failure Acute (100)
Dizziness (94)
Blood Pressure Increased (93)
Dyspnoea (80)
Rhabdomyolysis (72)
Renal Failure (67)
Hypotension (67)
Hyperkalaemia (63)
Malaise (56)
Asthenia (56)
Fall (55)
Fatigue (54)
Headache (53)
Nausea (52)
Hypertension (52)
Myocardial Infarction (51)
Cough (51)
Diarrhoea (51)
Cardiac Failure (48)
Blood Creatine Phosphokinase Increased (47)
Cerebrovascular Accident (47)
Atrial Fibrillation (46)
Cardiac Arrest (45)
Chest Pain (45)
Pneumonia (44)
Blood Creatinine Increased (44)
Hypoglycaemia (42)
Palpitations (41)
Pain (41)
Loss Of Consciousness (40)
Dehydration (40)
Hyponatraemia (39)
Anaemia (39)
Death (38)
Pain In Extremity (38)
Rash (38)
Overdose (36)
Cardiac Failure Congestive (36)
Arthralgia (36)
Alanine Aminotransferase Increased (33)
Myalgia (32)
Pruritus (32)
Oedema Peripheral (32)
Feeling Abnormal (32)
Back Pain (32)
Anxiety (31)
Blood Pressure Decreased (31)
Heart Rate Increased (31)
Adverse Event (30)
Abdominal Pain Upper (29)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Am a 76 year-old hypertensive with CKD; was given 'Cozaar' and 6 months into therapy developed excessive swelling of ankles/feet. Asked for GFR., and the result was 38, when I had been at a level of 54 for the previous 5 years. Ceased 'Cozaar' 4 mont

Back pain, horrible itching, confusion, insomnia, headache, did I mention back pain? It did bring down my blood pressure, No way I would even THINK of taking again. All this happened in 2 weeks! One of the WORST experiences of my life.

Do I need to register or hold membership to ask questions and get answers?

Got fluid ,back pain &headachs relly bad .dont want any more of this

Hello, Sorry to hear about you problems with this drug! YOU HAVE TO CHANGE YOUR MEDICIN ASAP!!! Ther is a lot of blood pressure medicin; hard to improv (I have done several times, use right now Coozar 50mg since 3 year, have to change asap becaus

I don't want to say my side-effects are from Cozaar alone, but I do feel a little different. I also take Metoprolol for my high blood. Anyway, I can't walk normally anymore. I'm a Carpenter by trade and that makes it 10 's harder. I walk with a limp.

I have been in a very debilitating state as far as sever muscle pain and injuries to the point i could barely walk i discontiued cozaar and am slowy getting back i believe with all my being it was due to cozaar and had to try to convince my dr. over

I have taken Cozaar for 8 years, never had a problem. My dose was 100 mg at night and 50 mg in morning. Suddenly out of the blue my blood pressure spiked to 185/135 and my heart went into a continuous fibrilation that lasted 2 hou

Ishave been on the same two med' and i too have had trouble with my legs. It is as you say, they are tired and I also get a burning feeling. I am taking 100 mg of cozaar and I am going to have the doc take me off.

HYPOKALAEMIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients
Condition: Peritoneal Membrane Failure
Interventions: Drug: placebo;   Drug: Aliskiren;   Drug: Aliskiren plus Losartan;   Drug: Enalapril plus Losartan
Outcome Measures: Changing in modified peritoneal equilibrium test;   appearance rate of dialysate CA125;   nutritional status;   adverse events
2 Unknown  Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients
Condition: Marfan Syndrome
Interventions: Drug: Losartan and nebivolol;   Drug: Losartan;   Drug: Nebivolol
Outcome Measures: BSA and age-adjusted aortic root diameter (sinuses of Valsalva);   The pharmacokinetics of the two drugs by age and dosages;   Comparative evaluation of the serum levels of total and active TGFb;   Quantitative assessment of the expression of the mutated gene (FBN1, both 5' and 3');   Pharmacogenetic bases of drug responsiveness (Losartan: CYP2C9 gene) (Nebivolol: CYP2D6 gene);   Aortic valve regurgitation severity;   Left ventricular end-diastolic diameter;   Left ventricular ejection fraction;   Spirometric lung volumes and flows;   QoL evaluation basing on SF-36 questionnaire;   Arterial stiffness (carotids)
3 Recruiting Losartan for Sickle Cell Kidney Disease
Condition: Sickle Cell Disease
Intervention:
Outcome Measures: Effects of Losartan;   chronic angiotensin blockade
4 Recruiting Anti-Fibrotic Effects of Losartan In Nash Evaluation Study
Condition: Nonalcoholic Steatohepatitis
Intervention: Drug: Losartan
Outcome Measures: The primary outcome will be change in Kleiner fibrosis score, [Kleiner DE et al Hepatology 2005], based on histological fibrosis stage (as judged by two independent blinded histopathologists from liver biopsies), from pre-treatment to end-of-study;   Change in radiological (fibroscan) and serological (ELF) markers of fibrosis;   change in NAFLD activity score (NAS);   comparison of "responder rate" - placebo versus intervention
5 Recruiting Study of Losartan in the Treatment of NAFLD in Children
Condition: NAFLD
Intervention: Drug: Losartan
Outcome Measures: Change in ALT from baseline to week 8 and/or week 22;   Changes in cholesterol and fatty acid levels;   Changes in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR), insulin and glucose;   Changes in Plasminogen activator inhibitor-1 (PAI-1)
6 Recruiting Cozaar XQ Re-examination Study (MK-0954-349)
Condition: Hypertension
Intervention: Drug: amlodipine/losartan
Outcome Measures: Number of participants with any adverse experience;   Change of sitting systolic and diastolic blood pressure (SiSBP, SiDBP) after treatment and overall efficacy evaluation by investigator
7 Not yet recruiting Comparison of Losartan Associated With Indapamide Versus Indapamide for Treatment of Hypertension
Condition: Hypertension
Interventions: Drug: Indapamide / Losartan;   Drug: Indapamide
Outcome Measures: Changes in systemic blood pressure measurements during 12 weeks;   Percentage (%) of patients with blood pressure < 140 / 90 mmHg during 12 weeks, will be obtained comparing the differences between initial blood pressure (initial visit) and final (final visit).;   Percentage (%) of patients excluded from the study because of treatment failure;   Time to appropriate control of systolic blood pressure and diastolic blood pressure (BP <140/90 mmHg.;   Incidence of any adverse events;;   Incidence of hypotension;   Incidence of serious adverse events and unexpected drug reactions
8 Recruiting Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: Losartan;   Drug: Placebo
Outcome Measures: The primary endpoint is to determine the impact of losartan treatment on lymphoid tissue (LT) fibrosis.;   We will assess the impact of losartan on immune reconstitution and function.;   We will determine the impact of losartan on immune activation in HIV infected, treated individuals.;   We will assess the potential for losartan to reduce the size of the viral reservoir.;   We will assess for any potential drug-drug interactions between losartan and antiretrovirals (ARVs).
9 Recruiting Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: FOLFIRINOX;   Drug: Losartan;   Radiation: Proton Beam Radiation
Outcome Measures: Feasibility of combining FOLFIRINOX-Losartan;   Progression-Free Survival;   Overall Survival for FOLFIRINOX + Proton Beam Radiation;   Overall Survival for FOLFIRINOX Without Proton Radiation;   Determine Toxicity FOLFIRINOX-Losartan;   Determine Toxicity of FOLFIRINOX-Losartan and Proton Beam Radiation;   Rate of Downstaging;   Determine correlation of Somatic Gene Mutations and Outcome;   Determine Correlation Between Circulating Biomarkers and Outcome
10 Recruiting Comparision of Blood Pressure Variability Between Amlodipine and Losartan
Condition: Hypertension
Interventions: Drug: Amlodipine;   Drug: Losartan
Outcome Measures: SD of visit-to-visit systolic blood pressure variability;   Central systolic blood pressure;   Augmentation index of central blood pressure;   Standard deviation of within-visit systolic blood pressure variability;   Coefficient of variation of visit-to-visit systolic blood pressure variability;   Variation independent of the mean of visit-to-visit systolic blood pressure variability;   24-h ambulatory blood pressure monitoring;   Home systolic blood pressure
11 Recruiting Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment
Conditions: Hypertension;   Sleep Apnea
Interventions: Drug: Losartan;   Other: CPAP
Outcome Measures: 24 h blood pressure (mean blood pressure; mmHg);   Markers of sympathetic activity, RAAS-activity, cardiovascular biomarkers
12 Recruiting The Effect of Losartan in Bicuspid Aortic Valve Patients
Conditions: Bicuspid Aortic Valve;   Thoracic Aortic Aneurysm
Intervention: Drug: Cozaar
Outcome Measure: Inflammatory markers level
13 Recruiting Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency
Condition: Renal Insufficiency, Chronic
Interventions: Drug: Benazepril;   Drug: Losartan;   Drug: Benazepril+Losartan
Outcome Measures: The proportion of patients with increase in serum potassium ≥6.0 mmol/L.;   The proportion of patients with serum creatinine increase >30%;   The proportion of patients with drug-related cough;   The proportion of patients with hopotension (systolic blood pressure <110 mmHg despite withdrawal of all additional antihypertensive medication);   The proportion of patients with non-fatal cardiovascular events
14 Unknown  A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome
Condition: Marfan Syndrome
Interventions: Drug: Losartan and Atenolol or Propranolol;   Drug: Atenolol or Propranolol
Outcome Measure: Echocardiograms
15 Recruiting Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
Conditions: Glomerulonephritis;   Proteinuria
Interventions: Drug: Shenyankangfu tablets;   Drug: Losartan potassium 50mg;   Drug: Shenyankangfu tablets and Losartan potassium 50mg;   Drug: Shenyankangfu tablets and Losartan potassium 100mg;   Drug: Losartan potassium 100mg
Outcome Measures: changes of 24 hours proteinuria after the treatment;   changes of serum creatinine after treatment;   changes of eGFR after the treatment;   changes of Traditional Chinese Medicine syndrome scores after the treatment
16 Recruiting Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
Conditions: Eosinophilic Esophagitis;   Connective Tissue Disorders
Intervention: Drug: Losartan Potassium
Outcome Measures: Number of participants with reduction of esophageal eosinophils;   Number of participants with reduction in levels of the transforming growth factor beta protein.;   Number of participants that experience normalization of the EoE transcriptome;   Number of participants that have an improved score utilizing the Patient Reported Outcome questionnaires to assess for clinical symptom response.;   Number of participants that have an improved score on the histology scoring system.;   To determine the safety of Losartan
17 Recruiting Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated
Condition: HIV-1
Interventions: Drug: EFV/FTC/TDF + Losartan;   Drug: EFV/FTC/TDF;   Drug: FTC/TDF + MK-0518;   Drug: FTC/TDF+MK-0518+Losartan
Outcome Measures: Proportion of patients with 50% reduction of fibrosis in lymphatic tissue.;   Proportion of patients with changes in the levels of IL-6, D-dimer and CRP in different groups.;   Proportion of patients with increased CD4 in peripheral blood and in lymphatic tissue.;   Proportion of patients with undetectable plasma viral load and decreased in lymphatic tissue in different groups;   Proportion of patients with changes in the CD4/CD8 ratio in peripheral blood in different groups.;   Proportion of patients with reduced intima-media complex in carotid ultrasound in different groups.;   Proportion of patients with changes in levels of metalloproteinases and their inhibitors, beta2-microglobulin and CSF cells and proteins.;   Proportion of patients with improvement in neuropsychological test CDS;   Incidence and types of adverse events and laboratory abnormalities in the different groups.
18 Recruiting Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers
Condition: Marfan Syndrome
Interventions: Drug: Losartan;   Drug: Placebo
Outcome Measures: The decrease of rate of aortic root growth measured by echocardiography at level of sinuses of Valsalva. The measure will be expressed in mm of growth per year and as Z-score.;   Comparative arterial stiffness;   Evaluation of progression of aortic regurgitation;   Aortic dissection incidence;   Aortic root surgery;   Progression of mitral regurgitation;   Left ventricular size and function;   Skeletal and somatic traits;   Quality of life;   Genetic polymorphisms affecting clinical symptoms and response to treatment;   Death;   Aortic stiffness as assessed by MRI
19 Unknown  PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites
Condition: Hypertension
Intervention: Drug: losartan
Outcome Measure:
20 Recruiting A Study of Muscle Strength Maintenance in Older Adults
Condition: Sarcopenia
Interventions: Drug: Losartan;   Drug: Placebo
Outcome Measures: Change from baseline in isokinetic strength and fatigability;   Change from baseline in frailty status